Isocitrate Dehydrogenase

"Isocitrate Dehydrogenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An enzyme of the oxidoreductase class that catalyzes the conversion of isocitrate and NAD+ to yield 2-ketoglutarate, carbon dioxide, and NADH. It occurs in cell mitochondria. The enzyme requires Mg2+, Mn2+; it is activated by ADP, citrate, and Ca2+, and inhibited by NADH, NADPH, and ATP. The reaction is the key rate-limiting step of the citric acid (tricarboxylic) cycle. (From Dorland, 27th ed) (The NADP+ enzyme is EC 1.1.1.42.) EC 1.1.1.41.

Descriptor ID	D007521
MeSH Number(s)	D08.811.682.047.820.475
Concept/Terms	Isocitrate Dehydrogenase Isocitrate Dehydrogenase Dehydrogenase, Isocitrate NAD Isocitrate Dehydrogenase Dehydrogenase, NAD Isocitrate Isocitrate Dehydrogenase, NAD Isocitrate Dehydrogenase (NAD+) Isocitrate Dehydrogenase-I Isocitrate Dehydrogenase-I Isocitrate Dehydrogenase I

Below are MeSH descriptors whose meaning is more general than "Isocitrate Dehydrogenase".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Oxidoreductases [D08.811.682]
Alcohol Oxidoreductases [D08.811.682.047]
NAD (+) and NADP (+) Dependent Alcohol Oxidoreductases [D08.811.682.047.820]
Isocitrate Dehydrogenase [D08.811.682.047.820.475]

Below are MeSH descriptors whose meaning is related to "Isocitrate Dehydrogenase".

Below are MeSH descriptors whose meaning is more specific than "Isocitrate Dehydrogenase".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Isocitrate Dehydrogenase" by people in this website by year, and whether "Isocitrate Dehydrogenase" was a major or minor topic of these publications.

Bar chart showing 12 publications over 7 distinct years, with a maximum of 4 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	0	1
2012	0	1	1
2015	1	3	4
2016	1	0	1
2018	1	1	2
2020	0	1	1
2022	1	1	2

Below are the most recent publications written about "Isocitrate Dehydrogenase" by people in Profiles.

Notarangelo G, Spinelli JB, Perez EM, Baker GJ, Kurmi K, Elia I, Stopka SA, Baquer G, Lin JR, Golby AJ, Joshi S, Baron HF, Drijvers JM, Georgiev P, Ringel AE, Zaganjor E, McBrayer SK, Sorger PK, Sharpe AH, Wucherpfennig KW, Santagata S, Agar NYR, Suv? ML, Haigis MC. Oncometabolite d-2HG alters T cell metabolism to impair CD8+ T cell function. Science. 2022 09 30; 377(6614):1519-1529.

View in: PubMed
Vachha BA, Huang RY. BOLD asynchrony: An imaging biomarker of tumor burden in IDH-mutated gliomas. Neuro Oncol. 2022 01 05; 24(1):88-89.

View in: PubMed
Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, Cachia D, Moshel Y, Brem S, Piccioni D, Landolfi J, Chen CC, Gruber H, Rao AR, Hogan D, Accomando W, Ostertag D, Montellano TT, Kheoh T, Kabbinavar F, Vogelbaum MA. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol. 2020 12 01; 6(12):1939-1946.

View in: PubMed
McBrayer SK, Mayers JR, DiNatale GJ, Shi DD, Khanal J, Chakraborty AA, Sarosiek KA, Briggs KJ, Robbins AK, Sewastianik T, Shareef SJ, Olenchock BA, Parker SJ, Tateishi K, Spinelli JB, Islam M, Haigis MC, Looper RE, Ligon KL, Bernstein BE, Carrasco RD, Cahill DP, Asara JM, Metallo CM, Yennawar NH, Vander Heiden MG, Kaelin WG. Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell. 2018 09 20; 175(1):101-116.e25.

View in: PubMed
Patel SA. Enasidenib-Induced Differentiation Syndrome in IDH2-Mutant Acute Myeloid Leukemia. JAMA Oncol. 2018 08 01; 4(8):1110-1111.

View in: PubMed
Mandel JJ, Cachia D, Liu D, Wilson C, Aldape K, Fuller G, de Groot JF. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neurooncol. 2016 08; 129(1):147-54.

View in: PubMed
Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, Suv? ML, Bernstein BE. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2016 Jan 07; 529(7584):110-4.

View in: PubMed
Kim J, Lee IH, Cho HJ, Park CK, Jung YS, Kim Y, Nam SH, Kim BS, Johnson MD, Kong DS, Seol HJ, Lee JI, Joo KM, Yoon Y, Park WY, Lee J, Park PJ, Nam DH. Spatiotemporal Evolution of the Primary Glioblastoma Genome. Cancer Cell. 2015 Sep 14; 28(3):318-28.

View in: PubMed
Cachia D, Kamiya-Matsuoka C, Mandel JJ, Olar A, Cykowski MD, Armstrong TS, Fuller GN, Gilbert MR, De Groot JF. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol. 2015 Nov; 125(2):401-10.

View in: PubMed
Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, Dubuc A, Brown L, Burns M, Cryan JB, Abedalthagafi M, Kang YJ, Schultz N, Reardon DA, Lee EQ, Rinne ML, Norden AD, Nayak L, Ruland S, Doherty LM, LaFrankie DC, Horvath M, Aizer AA, Russo A, Arvold ND, Claus EB, Al-Mefty O, Johnson MD, Golby AJ, Dunn IF, Chiocca EA, Trippa L, Santagata S, Folkerth RD, Kantoff P, Rollins BJ, Lindeman NI, Wen PY, Ligon AH, Beroukhim R, Alexander BM, Ligon KL. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.

View in: PubMed

People

Explore

Similar Concepts

Top Journals